Anticancer Activity of Limonia acidissima Linn (Rutaceae) Fruit Extracts on Human Breast Cancer Cell Lines by Pradhan, D et al.
Halder et al  
Trop J Pharm Res, June2012;11 (3): 413 
Tropical Journal of Pharmaceutical Research June 2012; 11 (3): 413-419 
© Pharmacotherapy Group,  
Faculty of Pharmacy, University of Benin,  
Benin City, 300001 Nigeria.  
All rights reserved. 
 





Anticancer Activity of Limonia acidissima Linn 
(Rutaceae) Fruit Extracts on Human Breast Cancer 
Cell Lines 
 
Debasish Pradhan1*, GitanjaliTripathy1 and Santosh Patanaik2 
1University Department of Pharmaceutical Sciences, Utkal University, Orissa751004, 2All India Institute of Medical 







Purpose: To evaluate the anti-cancer activity of Limonia acidissima Linn (Rutaceae) which has long 
been used traditionally for various infectious and malignant diseases.  
Methods: The fruit extract of Limonia acidissima Linn was obtained by macerating 3 times with 
methanol and then concentrating it at reduced pressure. Bioassay of the extract was carried out to 
assess the anticancer activity. Breast cancer cell lines, SKBR3 and MDA MB435, were used for in-vitro 
cell proliferation, cell viability assay, and cell cycle analysis of the extract.  
Results: Bioassay of the extract of Limonia acidissima Linn.  showed that a fraction (fraction 3) of the 
ethanol extract had anticancer activity against SKBR3 and MDA-MB435 human breast cancer cells. The 
effective dose (ED50) of Limonia acidissima Linn. fraction 3 was 56.1 and 30.6 μg/ml for SKBR3 and 
MDA-MB435, respectively. After 48 h of exposure, this fraction (100 μg/ml) significantly reduced cell 
proliferation in both cancer cell lines. In MDA-MB435 cells, cell cycle analysis showed that fraction 3 
induced the accumulation of cells in G2/M phase, but no significant change in cell cycle was detected in 
SKBR3 cells.  
Conclusion: The results indicate that the extract fraction could induce cell cycle arrest. However, 
further investigation is needed to assess the molecular mechanisms of the anticancer activities of this 
plant. 
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INTRODUCTION 
 
Breast cancer is one of the most prevalent 
malignancies in women worldwide. In India, 
breast cancer is the second to cervical 
cancer in frequency, with an estimated 
incidence rate of 17.2 per 100,000, and has 
increased in all parts of the country during the 
past decade  [1]. Although breast cancer 
therapy is usually multimodal, cytotoxic drugs 
still play important roles in increasing survival 
rate and quality of life [2]. Therefore, the 
development and search for novel and 
effective anticancer agents have become 
very important [3].  
 
To date, many cytotoxic agents including 
natural products isolated from plant sources 
have been investigated for discovery of 
potential novel anticancer drugs [4]. Higher 
plants have long been shown to be good and 
reliable sources for the development of novel 
anticancer drugs. In India, many plants have 
been used in the traditional treatment of 
various malignancies over the centuries.  
 
Limonia acidissima Linn, syn. Feronia limonia 
(Rutaceae) is a moderate-sized deciduous 
tree grown throughout India. The fruits are 
woody, rough and used as a substitute for 
bael in diarrheoa and dysentery [6,7]. The 
bark and leaves of the plant are used for 
vitiated conditions of vata and pita while the 
fruits are used for treating tumours, asthma, 
wounds, cardiac debility and hepatitis. The 
fruit contains flavonoids, glycosides, saponins 
and tannins [5]. Some coumarins [4,5] and 
tyramine derivatives [6] have also been 
isolated from the fruits of limonia. The leaves 
are reported to possess hepatoprotective 
activity [8] while the fruit shells contain 
antifungal compounds, namely, psoralene, 
xanthotoxin, 2, 6-dimethoxybenzoquinone 
and osthenol [9].  
 
However, the anticancer property of this plant 
has not yet been investigated. Therefore, this 
prompted us to investigate the inhibitory 
effect of the fruit extract of this plant on the 
growth of two different breast cancer cell 
lines, SKBR3 and MDA-MB435.  
EXPERIMENTAL 
 
Plant material and extraction procedures  
 
Ripe fruits of Limonia acidissima Linn.  were 
collected from the forest of Bhubaneswar hill 
situated in the eastern part of India in the 
month of May and identified by Dr SK Sahu, 
a taxonomist at Utkal University, Vanivihar, 
Orissa, India. A voucher specimen (no. 161) 
was deposited in the herbarium of the 
Department of Botany, Utkal University. The 
fruits were cut into small pieces and the pulp 
was separated. The pulp was shade-dried, 
milled and the powder (1.5 kg) macerated 
three times (for 7 days each) with 15 L of 95 
% ethanol at room temperature [6]. The 
extracts were concentrated under reduced 
pressure, at 60 0C resulting in a combined 




The extract (35 g) was dissolved in distilled 
water (100 ml) and 15 ml of the solution 
column chromatographed, dry packed using 
a glass column (inner diameter 4 cm, length 
60 cm), equilibrated with water (100 ml) and 
sonicated for 15 min in an ultrasonic bath. 
The detailed flow process is illustrated in Fig 
1. The suspension was centrifuged at 
20,000 rpm (approx. 42,000 g) for 30 min and 
then applied onto the Diaion® HP-20 column; 
the eluent was collected to get the water 
soluble fraction (fraction 1). The precipitate 
was dissolved in methanol–water (1:1, 
100 ml) and 90 % methanol (150 ml) to 
obtain fractions 2 and 3, respectively. Each 
supernatant was repeatedly treated as 
described above. The precipitate was 
dissolved in ethyl acetate to obtain fraction 4. 
The chemical composition of each fraction 
was monitored on TLC using silica gel GF254 
Alufolien (Merck) and developed with 
chloroform/ethanol (90:10, v/v). Phytosteryl 
glucoside was used as reference. After 
developing them, the TLC was sprayed with 
anisaldehyde-sulfuric acid and heated in an 
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Fig 1: Bioactivity-guided fractionation of Limonia acidissima fruit extract by column 
chromatography.  
 
Preparation of extracts for anticancer 
experiments  
 
The fruit extracts were dissolved in dimethyl 
sulfoxide (DMSO, Sigma, St. Louis, USA) 
except for the water fraction (fraction 1) which 
was dissolved in water. For all experiments, 
the final concentrations of the tested 
compounds were prepared by diluting the 
stock with the culture medium.  
 
Cell lines and culture 
 
The breast cancer cell lines, SKBR-3 (ATCC 
No. HTB-30) and MDA-MB435 (ATCC No. 
HTB-129), were procured from New Scientific 
Agencies, Bangalore, India. SKBR-3 is 
human breast cancer cell line with over-
expression of HER2/neu receptor and devoid 
of ER receptor while MDA-MB435 breast 
cancer cell line was devoid of both ER 
receptor and HER2/neu expression [7]. The 
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cells were cultured in DMEM (Promo Cell, 
Germany) supplemented with 10 % heat-
inactivated foetal bovine serum (Promo Cell, 
Germany) and 1 % penicillin-streptomycin 
(Promo Cell, Germany). The cells were 
incubated at 37 °C in a humidified 
atmosphere with 5 % CO2.  
 
 
Cell proliferation assay 
 
Cell proliferation assay was carried out by 
seeding a total of 1 × 104 cells per well in a 
96-well plate. After 36 h of incubation, various 
concentrations of fruit extracts were added to 
the wells to obtain final concentrations of 1, 
10, 100 and 500 μg/ml, respectively. Control 
groups were mixed with DMSO to obtain a 
final concentration of 1 %. Doxorubicin was 
used as positive control. The cells were 
incubated for an additional 48 h, 50 μl of MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide] (1 mg/ml, Sigma) in 
phosphate buffered saline (PBS) was added 
to each well, and incubated for 4 h at 37 °C. 
The medium was removed and formazan was 
dissolved in DMSO and the optical density 
measured at 590 mm using a bioassay 
reader (Biorad, USA) [9].  
 
Cell viability assay 
 
The cells were suspended in a 96-well plate 
at the same concentration as was used for 
the cell proliferation assay and then 
incubated for 24 h at 37 °C with 5 % CO2. 
Various concentrations of the fruit extract, as 
indicated above, were added to each well, 
with DMSO as control. After 48 h  of 
incubation, the cells were trypsinized and 
viable cell counting was performed by 
enumerating cells which excluded trypan blue 
dye using a haemocytometer.  
 
Cell cycle analysis 
 
To determine cell cycle, 1 × 106 cells were 
suspended in each tissue culture dish and 
treated with the fruit extract at final 
concentrations of 80 and 160 μg/ml for 
SKBR3. For MDA-MB435, cells were treated 
with the fruit extract at final concentrations of 
60 and 120 μg/ml. DMSO (1 %) was added to 
the control group. After treatment with fruit 
extract for 48 h, the cells were collected and 
incubated with reagents as described in the 
protocol of Cycle Test™ Plus DNA reagent kit 
(Becton Dickinson Immunocytometry 
System). The DNA content of the cells was 
measured by flow cytometry [10]. All samples 
were analysed within 3 h by FACS Carlibur 




The experiments were performed in triplicate. 
The data for cell proliferation and viability 
assays are expressed as mean ± standard 
deviation. ED50 values were calculated by 
regression analysis. A p value < 0.05 was 




The ethanol fraction revealed eight bands. 
Three bands were yellow-orange with Rf 
values of 0.12, 0.25 and 0.30. Five bands 
were violet-blue with Rf values of 0.17, 0.38, 
0.41, 0.56 and 0.61. The violet-blue reference 
compound appeared at the Rf value of 0.17.  
 
Growth inhibition by the fruit extract on 
human breast cancer cells is shown in Fig 2. 
At 48 h, the ED50 values of fraction 3 were 
56.1 ± 3.8 and 30.6 ± 1.5 μg/ml for SKBR3 
and MDA-MB435, respectively. Since fraction 
3 was found to have an inhibitory growth 
effect on these cell lines, this fraction was 
used to further investigate the effect of the 
fruit extract on these cells.  
 
Effect of extract on cell viability 
 
The results indicate that at a concentration of 
100 μg/ml, both cell lines showed low viability 
of < 50 % compared to that of the control 
group. No cell inhibition was observed at 
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Cell cycle induced by extract 
 
SKBR3 treated with fraction 3 at a final 
concentration of 160 μg/ml, shown in Fig 3, 
indicate a slight S phase block by decreasing 
the population of S phase from 12.9 to 7.2 %. 
For MDA-MB435 cell cycle progression, the 
result showed that the treated MDA-MB435 
cells (at a concentration of 120 μg/ml) 
increased the population of G2/M phase from 
24.4 to 45.7 % compared with that of the 









Fig 2: Inhibitory effect of  Limonia acidissima  
extract on SKBR3 (A) and MDA-MB435 (B) breast 




The ethanol extract of the plant fruit was 
fractionated in column chromatography, 
according to the compound polarity. The 
eluting solvents were transferred to the 
column, starting from water, water–methanol 
(1:1), methanol and ethyl acetate. They were 
subjected to MTT test for antiproliferative 
activities. The water soluble fraction 
comprised the most polar compounds, i.e., 
inorganic salts, sugars, amino acids, 
saponins; the water–methanol soluble 
fraction contains the glycosides while the 
ethyl acetate fraction is composed of 
aglycones. The methanol extract showed 
cytotoxicity against the SKBR3 and MDA-
MB435 breast cancer cell lines. This 
inhibitory growth activity of the treated cells 
acted in a dose-dependent manner which 
was also confirmed by the cell viability with 
the trypan blue exclusion assay. This 
observation suggests that some active 
components of this extract are in the 





Fig 3: Inhibition of cell cycle progression in breast 
cancer cell lines analysed by flow cytometry: (A) 
Cell cycle analysis of SKBR3 cells without plant 
extract at 48 h. GO/G1= 69.4 %, S = 12.9 %, 
G2/M = 15.1 %; (B) Cell cycle analysis of SKBR3 
cells after treatment with plant extract fraction 3 for 
48 h at 160 μg/ml: GO/G1 = 66.2 %, S = 7.2 %, 
G2/M = 19.6 % 
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Fig 4: (A) Cell cycle analysis of MDA-MB435 cells 
without treatment with plant extract. GO/G1 = 65.8 
%, S = 9.0 %, G2/M = 24.4 %; (B) Cell cycle 
analysis of MDA-MB435 cells following treatment 
with plant extract fraction 3 at 120 μg/ml for 48 h:  
GO/G1 = 36.8 %, S = 10.1 %, G2/M = 45.7 % 
 
SKBR3 cells treated with the fruit extract 
decreased in number in S phase, whereas 
MDA-MB435 treated with the extract 
remarkably accumulated in the G2/M phase 
of the cell. This indicates that fraction 3 is 
capable of suppressing breast cancer cell 
proliferation, especially MDA-MB435, via cell 
cycle blockage.  
 
Many anticancer agents derived from plants 
that are prescribed for treating malignancies 
inhibit cancer cell growth through cell cycle 
regulation, including G2/M accumulation [11].  
It is well known that agents that affect the 
G2/M phase cell cycle arrest act by targeting 
tubulin or disrupting tubulin-microtubule 
equilibrium [12,13]. Our findings indicate that 
Limonia acidissima fruit extract  exhibited 
antiproliferative effect on MDA-MB435 breast 
cancer cells via G2/M cell cycle arrest, and 
therefore may interact with tubulin in a 
manner similar to other plant-derived 
chemotherapeutic agents. However, the 
antiproliferative activities of this plant may 





Limonia acidissima Linn. fruit  fraction 3 
inhibits the proliferation of human breast 
cancer cell lines SKBR3 and MDA-MB435. 
The cell cycle via G2/M blockage plays some 
roles in Limonia acidissima Linn.-induced 
antiproliferative activities in MDA-MB435. 
However, further chemical and other 
investigations at molecular level are required 
to identify the active components that induce 
growth inhibition and to establish possible 
correlation between the observed activities of 
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